References
- El‐Deiry W S, Tokino T, Velculesco V E, et al. WAFI, a potential mediator of p53 suppression. Cell 1993; 75: 817–25
- Lane D P. p53, guardian of the genome. Nature 1992; 358: 15–6
- Levine A J, Pery M E, Chang A, et al. The 1993 Walter Hubert Lecture: The role of the p53 tumour‐suppressor gene in tumorigenesis. Br J Cancer 1994; 69: 409–16
- Harris C C, Hollstein M. Clinical implications of the p53 tumour‐suppressor gene. N Engl J Med 1993; 329: 1318–1327
- Thor A D, Moore D H, II, Edgerton S M, et al. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845–55
- Allred D C, Clark G M, Elledge R, et al. AsSociation of p53 protein expression with tumor cell proliferation rate and clinical outcome in node‐negative breast cancer. J Natl Cancer Inst 1993; 85: 200–6
- Stenmark‐Askmalm M, Stål O, Sullivan S, et al. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 1994; 30A: 175–80
- Hickman J A. Apoptosis induced by anticancer drugs. Cancer Metast Rev 1992; 11: 121–39
- Gorczyca W, Bigman K, Mittelman A, et al. Induction of DNA strand breaks asSociated with apoptosis during treatment of leukemias. Leukemia 1993; 7: 659–70
- Lowe S W, Ruley H E, Jacks T, Housman D E. p53–dependent apoptosis modulates the cytotoxity of anticancer agents. Cell 1993; 74: 957–67
- Kinzler K W, Vogelstein B. Clinical implications of basic research. Cancer therapy meets p53. N Engl J Med 1994; 331: 49–50
- Chin K ‐V, Ueda K, Pastan I, Gottesman M M. Modulation of activity of the promoter of the human MDRl gene by ras and p53. Science 1992; 255: 459–62
- Rutqvist L E, Cedermark B, Glas U, et al. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomised trials. Int J Radiat Oncol Biol Phys 1989; 16: 629–39
- Stil O, Skoog L, Rutqvist L E, et al. S‐phase fraction and survival benefit from adjuvant chemotherpy or radiotherapy. Br J Cancer 1994; 70: 1258–62
- Vindelöv L L, Christensen I B J, Nissen N I. A detergent‐trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 323–7
- Cox D R. Regression models and life tables (with discussion). J Stat Soc B 1972; 34: 187–220
- Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81
- Livingstone L R, White A, Sprouse J, Livanos E, Jacks T, Tisty T D. Altered cell cycle arrest and gene amplification potential accompany loss of wild‐type p53. Cell 1992; 70: 923–35
- Cross S M, Sanchez C A, Morgan C A, et al. A p53–dependent mouse spindle checkpoint. Science 1995; 267: 1353–6
- el Rouby S, Thomas A, Costin D. p53 gene mutation in B‐cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452–9
- Nelson W G, Kastan M B. DNA strand breaks: the DNA template alterations that trigger p53–dependent DNA damage response pathways. Mol Cell Biol 1994; 14: 1815–23
- Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumour‐suppressor protein p53 by DNA‐damaging agents. Oncogene 1993; 8: 307–18